

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	09/699,003
(use as many sheets as necessary)		Filing Date	October 26, 2009
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	3761
		Examiner Name	Leslie R. Deak
		Attorney Docket Number	LEN 101 CIP CON
Sheet	1	of	3

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
		PCT	WO 03/056896		Molecular Staging, Inc.	07-17-2003		
		RU	2 130 069 (w/ Engl. Abstract)		Inst Ehlemento-organicheskikh S	05-10-1999		
Examiner's Signature					Date Considered			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/699,003
Sheet	2	of	3
Filing Date	October 26, 2009		
First Named Inventor	M. Rigdon Lentz		
Group Art Unit	3761		
Examiner Name	Leslie R. Deak		
Attorney Docket Number	LEN 101 CIP CON		

OTHER ART – NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		ADOLF and FRÜHBEIS, "Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity.", <i>Cytokine</i> , 4(3):180-184 (1992).
		BJORNBERG, et al., "Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms", <i>Lymphokine Cytokine Res.</i> , 13(3):203-11 (1994).
		COLMAN, et al., <i>Hemostasis and Thrombosis: Basic Principles and Clinical Practice</i> 2nd Ed., Colman, R.W., et al., p. 242-267 (J.B.Lippincott, Philadelphia, PA 1987).
		GADDUCCI, et al., "Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer", <i>Gynecol Oncol</i> , 58(2):184-8 (1995).
		GRELL, et al., "The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor", <i>Proc Natl Acad Sci U S A</i> , 95(2):570-5 (1998).
		GROSEN, et al., "Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy", <i>Gynecol Oncol</i> , 50(1):68-77 (1993).
		HASEGAWA, et al., "Increased soluble tumor necrosis factor receptor levels in the serum of elderly people", <i>Gerontology</i> , 46(4):185-8 (2000).
		JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," <i>Arch Immunol Ther Exp (Warsz)</i> . 45(5-6):449-53 (1997).
		JABLONSKA, et al., "Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients", <i>Eur Cytokine Netw</i> , 9(2):155-9 (1998).
		LAUCELLA, et al., "Papel de las citoquinas en la resistencia y patología durante la infección con <i>Trypanosoma cruzi</i> " <i>Revista Argentina de Microbiología</i> , 28:99-109 (1996) (with English Abstract).
		MACALLAN, et al., "Development of a novel TNF alpha ligand-receptor binding assay for screening NATCHEM Libraries", <i>J Recept Signal Transduct Res</i> , 17(1-3):521-9 (1997). (with English Abstract)

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>	<p>Complete if Known</p>												
	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 65%;">Application Number</td> <td style="width: 35%;">09/699,003</td> </tr> <tr> <td>Filing Date</td> <td>October 26, 2009</td> </tr> <tr> <td>First Named Inventor</td> <td>M. Rigdon Lentz</td> </tr> <tr> <td>Group Art Unit</td> <td>3761</td> </tr> <tr> <td>Examiner Name</td> <td>Leslie R. Deak</td> </tr> <tr> <td>Attorney Docket Number</td> <td>LEN 101 CIP CON</td> </tr> </table>	Application Number	09/699,003	Filing Date	October 26, 2009	First Named Inventor	M. Rigdon Lentz	Group Art Unit	3761	Examiner Name	Leslie R. Deak	Attorney Docket Number	LEN 101 CIP CON
Application Number	09/699,003												
Filing Date	October 26, 2009												
First Named Inventor	M. Rigdon Lentz												
Group Art Unit	3761												
Examiner Name	Leslie R. Deak												
Attorney Docket Number	LEN 101 CIP CON												
Sheet	3												
of	3												

#### **OTHER ART – NON PATENT LITERATURE DOCUMENTS**

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.